Navigation Links
ViaCyte Announces Executive Management Changes
Date:8/9/2011

SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- ViaCyte, Inc. today announced changes to its  executive management team, including the appointment of Allan Robins, Ph.D., as Acting Chief Executive Officer, and the promotion of Kevin D'Amour, Ph.D., to Chief Scientific Officer.

Robins continues to serve as Vice President and Chief Technology Officer, and his appointment as acting CEO follows the departure of President and Chief Executive Officer John West who resigned for personal reasons. West continues his relationship with ViaCyte as a consultant and as a member of its Board of Directors. The Board has initiated a search for a new CEO.

"Allan has successfully led our process development and manufacturing operations since our merger with BresaGen in 2004 and has made a number of significant contributions to ViaCyte's research and technology platform.  We're pleased to have Allan assume this important interim CEO role. We also thank John West for his leadership and for his achievements in extending our company's funding resources," said Fred Middleton, Chairman of ViaCyte.

Prior to ViaCyte, Robins served as Chief Scientific Officer at BresaGen, Inc., the United States subsidiary of BresaGen Limited, an Australian biotechnology company that has since been acquired by Hospira, Inc.  Under Robins' leadership, BresaGen secured significant support from the National Institutes of Health for its stem cell research. Robins received his Ph.D. in molecular biology from the University of Adelaide in Australia and completed postdoctoral work at Cambridge University in England.

"I welcome the opportunity to serve in this expanded role as our forward progress continues," said Robins.  Commenting on D'Amour's promotion, Robins noted:

"Kevin has been essential in the development of our scientific program and is a world renowned stem cell expert.  As CSO, Kevin will lead the alignment of ViaCyte's research strategy with its b
'/>"/>

SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cellular Dynamics Licenses Technology From ViaCyte
2. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
3. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
4. Osteologix Announces Completion of Corporate Consolidation
5. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
6. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
7. Rigel Announces Second Quarter 2011 Financial Results
8. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
9. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
10. International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices
11. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... According to new market research report "Cloud ... Deployment & Support), by Service Model (SaaS, PaaS, ... (Hybrid & Community)) - Global Forecast to 2019", ... Professional Services Market into various sub-segments with an ... identifies the drivers and restraints for this market ...
(Date:10/22/2014)... HONG KONG , Oct. 22, 2014 ... enterprise, announced today that rare disease expert John ... president, research. Dr. McKew brings more than two decades ... at the National Institutes of Health, Wyeth Research and ... McKew will lead aTyr,s efforts to expand and translate ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
Breaking Biology Technology:Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... , , , , ALISO VIEJO, ... VRX ) today reported final results for its Phase IIb ... is in development for the treatment of chronic hepatitis C ... treatment naive genotype 1 infected subjects was of standard design, ...
... activity in breast cancer patients with high expression of ... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, presented data from a ... in combination with the chemotherapeutic docetaxel in patients with ...
... ... crops Knowledge Platform ,CJP,s "3rd Global Jatropha Hi-Tech Agricultural Training Programme ... provide the most authoritative Knowledge platform for Development of Sustainable Non-Food ... Biodiesel Industry Worldwide. The biodiesel industry has met a lot of ...
Cached Biology Technology:Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 3Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 5Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 2Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 3Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform 4
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... Law Enforcement Data Sharing Consortium Now Includes over ... International, Inc. (OTC Bulletin Board: BKYI), a leader ... solutions, today announced a contract award from the ... law enforcement mobile data solution. Using MobileCop on ...
... The New Jersey Chapter of the American Society of ... Year Award to John Schuring, Stabile Professor for Innovation ... as an expert, contact Sheryl Weinstein at 973-596-3436.) ... environmental engineering, has 35 years of experience in the ...
... ago, the oil tanker Exxon Valdez was exiting Alaska,s Prince ... of the night. What happened next is considered one of ... oil spilled into the pristine Alaskan waters, eventually covering 11,000 ... times the amount of oil spilled in the Exxon Valdez ...
Cached Biology News:Tulsa County Sheriff Selects BIO-key(R) Mobile Data System 2Civil engineers name NJIT's John Schuring Educator of Year 2UCSB scientists document fate of huge oil slicks from seeps at coal oil point 2UCSB scientists document fate of huge oil slicks from seeps at coal oil point 3UCSB scientists document fate of huge oil slicks from seeps at coal oil point 4
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Imject Freund's Complete Adjuvant (FCA)...
... stain was developed specifically for reduced mutagenicity ... DNA in agarose or acrylamide gels. SYBR Safe ... bromide but SYBR Safe stain's detection sensitivity is ... stain comes as a premixed solution that can ...
... nucleic acid gel stain is an exceptionally ... fluorescence when bound to dsDNA and low background ... in gels using laser scanners or standard UV ... also found uses in capillary electrophoresis, real-time PCR ...
Biology Products: